COMPANY

Neurocentria

HQ: Walnut Creek, CA source · neurocentria.com ↗

Keywords: neurology psychiatry attention deficit hyperactivity disorder depression Alzheimer's disease ADHD Attention-Deficit/Hyperactivity Disorder Anxiety Sleep Quality Cognitive Impairment Alzheimer Disease NRCT-101SR NRCT-101SR, NRCT-202XR NRCT-101-SR

Location: Walnut Creek, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

5Trials (company is sponsor)

Timeline

Feb 25, 2025 Trial start 2: A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attentio source ↗
Jan 25, 2024 Trial start Phase 2/Phase 3: Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD source ↗
Feb 25, 2023 Trial start Phase 2/Phase 3: Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD) source ↗
Jul 23, 2018 Trial start Phase 2: Comparison of MMFS Dosages in Older Adults source ↗
Mar 20, 2018 Trial start Phase 2: Efficacy and Safety of MMFS in Early AD source ↗

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT06215144	Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD	Phase 2/Phase 3	Terminated	Jan 25, 2024	Oct 10, 2025 (actual)
NCT06673368	A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder	2	Terminated	Feb 25, 2025	Jul 15, 2025 (actual)
NCT05683249	Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)	Phase 2/Phase 3	Completed	Feb 25, 2023	Jan 17, 2024 (actual)
NCT03601169	Comparison of MMFS Dosages in Older Adults	Phase 2	Completed	Jul 23, 2018	Jan 31, 2019 (actual)
NCT03531684	Efficacy and Safety of MMFS in Early AD	Phase 2	Completed	Mar 20, 2018	Apr 22, 2020 (actual)